LDK378

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

LymphomaNon-Small Cell Lung CancerHilar Cholangiocarcinoma

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

1

Blenoxane

SSequus Pharmaceuticals

Preclinical

252

Oncaspar

SServier

Preclinical

153

Zofran

Novartis

Preclinical

24

LDK378

Novartis

Phase 2

25

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

46

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

17

Kenalog

BBausch Health Americas, Inc.

Preclinical

18

Nuvigil

NNuvo Research GmbH

Preclinical

19

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—10

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1Show 24 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer6 trials

An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement

Unknown status·YYonsei University·Phase 2·NCT01964157·32 enrolled

A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer

Completed·Novartis·Phase 2·NCT02276027·66 enrolled

LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

Completed·Novartis·Phase 2·NCT01685138·124 enrolled

Show 3 more trials

Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer

Completed·Novartis·Phase 1·NCT01772797·22 enrolled

LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Completed·Novartis·Phase 1/2·NCT02040870·103 enrolled

A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement

Unknown status·YYonsei University·Phase 2·NCT03399487·46 enrolled

Lymphoma2 trials

Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)

Completed·Novartis·Phase 1·NCT01634763·22 enrolled

A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase

Completed·Novartis·Phase 1·NCT01283516·304 enrolled

Hilar Cholangiocarcinoma1 trial

A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma

Terminated·NNational Health Research Institutes, Taiwan·Phase 2·NCT02374489·9 enrolled

Treatment1 trial

Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

No longer available·Novartis··NCT01947608

Hepatic Impairment1 trial

Effect of Hepatic Impairment on LDK378 Pharmacokinetics

Completed·Novartis·Phase 1·NCT01950481·36 enrolled

2 more indications

Chemotherapy1 trial

LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

Completed·Novartis·Phase 2·NCT01685060·140 enrolled

ALK Positive1 trial

LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.

Completed·Novartis·Phase 2·NCT02450903·20 enrolled

Details

Drug Info

Related News